REMEDY Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act
This bill addresses drug patents with respect to Food and Drug Administration (FDA) approval of a drug application.
Currently, when the owner of a brand-name drug approval sues a generic drug company for patent infringement based on the generic company's application for FDA approval of a generic version of the brand-name drug, there is generally a 30-month stay on the approval of the generic version. Under this bill, the stay goes into effect only if the lawsuit alleges infringement of a patent that claims the drug compound.
When the U.S. Patent and Trademark Office invalidates a patent for a drug, the FDA must update its list of relevant patents for the drug.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 1209: REMEDY Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-1209/
"S. 1209: REMEDY Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-1209/.
S. 1209, 116th Cong. (2026), https://openamerica.io/bill/116-S-1209/.
[S. 1209: REMEDY Act](https://openamerica.io/bill/116-S-1209/)